MLLCF (MLLCF) Stock Price & Analysis
MLLCF (MLLCF) fell 47.42% to USD 2.55 as of June 10, 2026 at 03:44 UTC, according to Nexqual real-time market data.
MLLCF last closed at USD 4.85; the session ranged USD 2.55–2.55 on volume of 100 shares. Market capitalization is $95.65M, with a 52-week range of USD 2.25–4.85 (PNK). Source: Nexqual, June 10, 2026 at 03:44 UTC.
Key Statistics (as of June 10, 2026 at 03:44 UTC)
| Price | USD 2.55 |
|---|---|
| Change | ▼ 47.42% (down) |
| Previous Close | USD 4.85 |
| Open | USD 2.55 |
| Day Range | USD 2.55 – 2.55 |
| 52-Week Range | USD 2.25 – 4.85 |
| Volume | 100 shares |
| Market Cap | $95.65M |
| Exchange | PNK |
Technical Analysis (MLLCF)
Nexqual's technical model rates MLLCF "BUY" based on 5 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 03:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 2.95) |
| MACD | 0.64 (positive) |
Analyst Ratings (MLLCF)
Wall Street analysts rate MLLCF "None", per Nexqual as of June 10, 2026 at 03:44 UTC.
| Consensus Rating | None |
|---|
Earnings (MLLCF)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financials & Fundamentals (MLLCF)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -59.01% |
| Debt / Equity | 4.89 |
| Current Ratio | 9.43 |
| Total Cash | $78.77M |
| Total Debt | $3.34M |
| Free Cash Flow | $-25.20M |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financial Health Score (MLLCF)
Nexqual rates MLLCF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:44 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $79M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$48M |
| Efficiency | Critical — ROE -59%, ROA -28.8% |
Ownership (MLLCF)
| Insider Ownership | +8.47% |
|---|---|
| Institutional Ownership | +43.96% |
| Shares Outstanding | 37.51M |
| Float | 19.92M |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Leadership (MLLCF)
MLLCF is led by Patrick Amstutz (age 50), Co-Founder, CEO, Member of Management Board & Director, per Nexqual as of June 10, 2026 at 03:44 UTC.
| Co-Founder, CEO, Member of Management Board & Director | Patrick Amstutz (age 50) |
|---|---|
| COO & Member of Management Board | Alexander Zurcher (age 50) |
| Chief Scientific Officer & Member of the Management Board | Martin Steegmaier (age 59) |
| Senior Vice President of Targeted Radio Therapeutics | Daniel Steiner |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MOLN | Molecular Partners AG | USD 3.88 | ▼ 5.37% |
| CLVLF | Clinuvel Pharmaceuticals Ltd. | USD 6.4 | ▲ 0% |
| CLVLY | Clinuvel Pharmaceuticals Ltd. | USD 6.36 | ▼ 3.64% |
| OXBDF | Oxford Biomedica PLC | USD 8.44 | ▲ 6.63% |
| INRLF | Valneva SE | USD 2.8 | ▲ 2.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:44 UTC. This page is informational and not investment advice.